RANK-ligand-hemming for å bekjempe sarkopeni med underliggende osteoporose
RANK-ligand-hemming for å bekjempe sarkopeni med underliggende osteoporose: en randomisert, dobbeltblind, dobbeldummy, aktivt kontrollert forsøk
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Aims:
- To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
- To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Ronald Man Yeung Wong
- Telefonnummer: 852 3505 1654
- E-post: ronald.wong@cuhk.edu.hk
Studiesteder
-
-
-
Hong Kong, Kina
- Rekruttering
- The Chinese University of Hong Kong
-
Ta kontakt med:
- Ronald Man Yeung Wong
- Telefonnummer: 852 3505 1654
- E-post: ronald.wong@cuhk.edu.hk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Elderly males or females aged 65 years or older
- diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
- Willing and able to comply with study protocol including follow-up evaluations.
Exclusion Criteria:
- history of recent fracture i.e., within 3 months
- history of prior anti-osteoporotic drug
- disease or medication affecting bone or muscle metabolism
- Chairbound or bedbound
- Unable to agree for consent
- contraindication to drug i.e., Denosumab or Zoledronic Acid
- Underlying malignancy or disease known to cause cachexia
- severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
- moderate to severe liver failure (Child-Pugh Class B or C).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Denosumab group
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
|
Placebo komparator: Zolendronic acid group
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
6-metre walk
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as &lt;1.0m/s. |
From enrollment to the end of treatment at 52 weeks
|
|
5-time chair stand test
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
The time to rise from a chair 5 times is recorded. The cut-off for is taken at &gt;=12 seconds. |
From enrollment to the end of treatment at 8 weeks
|
|
Appendicular skeletal muscle mass (ASM)
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is &lt; 7 kg/m2 for men and 5.4 kg/m2 for women. |
From enrollment to the end of treatment at 52 weeks
|
|
Handgrip strength
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is &lt; 28kg, and female is &lt;18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction |
From enrollment to the end of treatment at 52 weeks
|
|
Quadriceps muscle strength
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%). |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s) |
From enrollment to the end of treatment at 52 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Falls
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year |
From enrollment to the end of treatment at 52 weeks
|
|
Fracture
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Assess occurrence of a fracture within a year of study period. |
From enrollment to the end of treatment at 52 weeks
|
|
Quality of life Short Form-36 (SF-36)
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life. |
From enrollment to the end of treatment at 52 weeks
|
|
Physical activity scale for elderly (PASE)
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity |
From enrollment to the end of treatment at 52 weeks
|
|
Food frequency questionnaire
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong. |
From enrollment to the end of treatment at 52 weeks
|
|
Hospital admissions
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Number and cause of emergency hospital admission within 1 year of study period are documented. |
From enrollment to the end of treatment at 52 weeks
|
|
Mortality
Tidsramme: From enrollment to the end of treatment at 52 weeks
|
Mortality within 1-year of study period is documented. |
From enrollment to the end of treatment at 52 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2022.555
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .